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Phase II Study of Biweekly Pemetrexed and Gemcitabine in
Patients with Previously Untreated Advanced Non-small
Cell Lung Cancer
David R. Spigel, MD,*† John D. Hainsworth, MD,*† John H. Barton, MD,† Jeffrey F. Patton, MD,*†
John D. Zubkus, MD,† Lisa Simons, CCRP,* Paula Griner, BS, CTR,* Howard A. Burris, III, MD,*†
and F. Anthony Greco, MD*†
Introduction: Pemetrexed and gemcitabine are safe and active
non-small cell lung cancer (NSCLC) therapies when adminis-
tered every 3 weeks. Biweekly scheduling was studied in this
phase II trial.
Methods: The primary objective was to assess the overall response
rate in chemotherapy-naive patients with unresectable stage III/IV
NSCLC. Patients received 500 mg/m2 of pemetrexed intravenously
and 1500 mg/m2 of gemcitabine intravenously every 2 weeks for 8
to 12 cycles with restaging every 4 cycles. Patients also received
supplemental folate/B12 therapy. Entry criteria included the follow-
ing: all non-small cell histologies, measurable disease, Eastern
Cooperative Oncology Group 0 to 2, and informed consent.
Results: Seventy-two patients were enrolled. Baseline characteris-
tics included the following: median age: 66 years (41–85 years);
male/female: 65%/35%; Eastern Cooperative Oncology Group
0/1/2: 19%/67%/14%; and histology: adenocarcinoma (36%), large
cell (18%), squamous (13%), and mixed or not specified (34%). The
median number of cycles was 7 (range, 1–12). The most common
(5%) grade 3/4 toxicities were as follows: neutropenia (47%),
leukopenia (31%), fatigue (25%), dyspnea (18%), pain (11%), and
anemia (8%). Complete/partial responses for all patients: 1 pa-
tient/18 patients, respectively, for an overall response rate of 26%
(95% confidence interval, 17–38%). Thirty-nine percentage of pa-
tients had stable disease, and 21% had disease progression (10
patients were not evaluable). Median progression-free survival was
6.2 months. One-year overall survival was 37.5%.
Conclusion: Biweekly administration of pemetrexed and gemcitab-
ine seems to be well tolerated with activity comparable with other
first-line NSCLC regimens. Further study addressing whether bi-
weekly scheduling could be an effective strategy to shorten overall
treatment duration will require a randomized design.
Key Words: First-line, Non-small cell lung cancer, Pemetrexed,
Gemcitabine, Phase II.
(J Thorac Oncol. 2010;5: 841–845)
Chemotherapy improves survival in patients with ad-vanced non-small cell lung cancer (NSCLC).1 Many
regimens are considered standard in the first-line setting
because of similar survival benefits, including nonplatinum
combinations.2–5 Choosing the optimal regimen for a partic-
ular patient often depends on a regimen’s safety profile and
ease of administration. One such potential regimen includes
the antifolate pemetrexed and antimetabolite gemcitabine,
each generally well tolerated and among the safest agents
used in NSCLC treatment.6–9
This doublet regimen has been studied in combination
in three 21-day schedules in a randomized phase II trial in
patients with newly diagnosed advanced NSCLC.10 Efficacy
was similar across cohorts and comparable with other first-
line treatments (median survival, 11.4 months). The least
toxic schedule was 500 mg/m2 of pemetrexed plus 1250
mg/m2 of gemcitabine on day 1 followed by gemcitabine
alone on day 8 (every 21 days). More recently, Melemed et al.11
evaluated this combination in a phase I study using a bi-
weekly schedule. The established dosing for phase II study
was 500 mg/m2 of pemetrexed plus 1500 mg/m2 of gemcit-
abine on every 14 days.
In theory, biweekly scheduling could improve the dose
intensity and treatment response. Herein, we report on a
phase II trial where pemetrexed and gemcitabine were ad-
ministered biweekly in the patients with previously untreated
advanced NSCLC.
PATIENTS AND METHODS
This trial was initiated in May 2005. The participat-
ing centers included the Sarah Cannon Research Institute
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and offices within Tennessee Oncology, PLLC in middle
Tennessee.
Patients
Patients with histologically confirmed NSCLC were
enrolled. Patients with newly diagnosed unresectable stage
IIIB or IV disease were eligible. Patients with stage III
disease had to be ineligible for combined modality therapy
(i.e., pleural effusions, pericardial effusions, etc). Patients had
measurable disease per RECIST.12 Other eligibility criteria
included the following: age 18 years, no prior chemother-
apy, absence of active brain metastases, Eastern Cooperative
Oncology Group performance status 0 to 2 (ranging from
normal to ambulatory, but unable to carry out any work
activities), and adequate organ function (defined as absolute
neutrophil count [ANC] 1.5  109/liter, platelet count
100  109/liter, serum aspartate aminotransferase and ala-
nine aminotransferase 5, serum bilirubin 1.5, the
upper limit of normal, and serum creatinine 2 mg/dl).
Exclusion criteria included the following: pregnancy
or lactation, clinically significant cardiovascular disease,
active infection, and prior malignancy within 5 years
except nonmelanoma skin cancer and cervical carcinoma
in situ. All patients provided written informed consent
before enrollment.
Pretreatment Evaluation
Before treatment, patients were evaluated by history,
physical examination, and laboratory testing. Baseline tumor
staging was performed using computerized tomography (CT)
scans of the chest, imaging of the brain, and positron emis-
sion tomography.
Treatment Plan
All patients received 500 mg/m2 of pemetrexed admin-
istered intravenously over 10 minutes, immediately followed
by 1500 mg/m2 of gemcitabine administered intravenously
over 30 minutes, both on day 1 of each 14 day cycle.
Treatment was continued for a maximum of 12 cycles.
Patients were restaged with CT scans every four cycles (per
RECIST). After completion of protocol therapy, patients
were followed up for recurrence with history and physical
examination, complete blood counts, chemistry profile, and
chest radiographs for every 2 months during the first year,
every 3 months during the second year, and every 6 months
thereafter. Any evidence suggesting progression was fol-
lowed by appropriate clinical evaluation, including CT scan-
ning and/or positron emission tomography scanning.
Dose modifications were based on ANC and platelet
counts on day 1 of each cycle (dose level 1: pemetrexed 400
mg/m2/gemcitabine 1200 mg/m2; dose level 2: pemetrexed
300 mg/m2/gemcitabine 900 mg/m2). Doses were not in-
creased once modified. No adjustments were required if the
ANC was 1.5  109/liter and platelet count 100 
109/liter. If the ANC was 1.5  109/liter or platelets
100 109/liter, chemotherapy was held until counts recov-
ered to baseline parameters when chemotherapy could be
resumed with one dose level reduction. If the counts did not
recover within 2 weeks, the patient came off study. Patients
requiring hospitalization for neutropenia and fever had dose
reductions. Chemotherapy doses were also reduced for grade
3/4 nonhematologic toxicity.
Toxicity assessments were made according to the com-
mon terminology criteria for adverse events (CTCAE version
3.0) of the National Cancer Institute. Cytokines were not
administered with the first course of treatment. Prophylactic
granulocyte colony-stimulating factor for patients experienc-
ing febrile neutropenia was permitted at the discretion of the
treating physician but was not to substitute for mandated dose
reductions. Folic acid and vitamin B12 were given because of
their ability to reduce pemetrexed toxicity. Folic acid (350–
1000 g; or an equivalent) was taken orally daily beginning
approximately 1 to 2 weeks before the first dose of pem-
etrexed and continued daily until 3 weeks after the last dose
of pemetrexed. Vitamin B12 (1000 g) was administered
intramuscularly approximately 1 to 2 weeks before the first
dose of pemetrexed and repeated approximately every 9
weeks until 3 weeks after the last dose of pemetrexed.
Dexamethasone (4 mg) was given orally twice daily the day
before, the day of, and the day after pemetrexed as a prophy-
lactic measure against skin rash. Routine antiemetics were
used as premedication.
This trial was approved by the institutional review
boards of all participating institutions. Pemetrexed was pro-
vided by Eli Lilly and Co.; and the commercially available
forms of gemcitabine were used.
Definition of Response
All patients were evaluated for response by RECIST
criteria. The final response category assigned represented the
best response obtained during treatment.
Statistical Methods
The primary objective of this phase II study was to
assess the overall response rate (ORR). Secondary objectives
were to assess the progression-free survival (PFS), median
overall survival (OS), and treatment-related toxicity.
Based on data from other studies, a response rate of
25% would be of interest for this combination regimen. By
contrast, a response rate of 10% would not justify further
study. This trial used a design based on a Simon two-stage
accrual plan. If at least two responses were seen in the first 21
patients, an additional 49 patients would be treated. If the
regimen had two or fewer responses, then the trial would
stop. Seventy patients would be required to achieve this
objective (alpha level 0.05 and power 0.9).
An early stopping rule was present for toxicity. If, at the
time of the interim efficacy analysis in the first stage, it was
found that 30% of patients experienced grade 4 hemato-
logic or nonhematologic toxicity or grade 3 or 4 hepatic
toxicity, accrual would be terminated.
PFS was defined as the interval between the start date
of treatment and the date of occurrence of progressive disease
or death from any cause. OS was measured from the date of
study entry until the date of death. Toxicity was evaluated in
all patients who received at least one dose of therapy. If there
was intolerable toxicity or discontinuation of treatment sec-
ondary to toxicity, the patient was considered assessable, but
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it was classified as a treatment failure. If other cancer therapy
was initiated before progressive disease occurred, the patient
was censored on the date on which the other therapy began.
If a patient was lost to follow-up, the patient was censored on
the date of last contact. Survival curves were constructed
using the method of Kaplan and Meier.13
RESULTS
Patient Characteristics
Seventy-two patients were enrolled from May 2005 to
April 2006, all from Tennessee. Baseline characteristics for
all patients are described in Table 1.
Treatment Received
The median number of cycles administered was 7
(range, 1–12). Thirty-five (49%) patients completed more
than eight cycles of chemotherapy, and 14 (19%) patients
completed 12 cycles. Thirty-five (49%) patients received
subsequent therapy. The dose modifications were made for
pemetrexed and gemcitabine in 18% and 17% of patients,
respectively.
Response
Seventy-two patients are included in the response anal-
ysis. Ten (14%) patients were not evaluable for a response
because of treatment-related toxicity (two patients; dyspnea,
and pancytopenia), intercurrent illness (two patients; stroke
and heart failure), treatment delay,1 physician discretion,4 or
patient request.1 One patient (1%) had a complete response,
and 18 (25%) patients had partial responses, for an ORR of
26% (95% confidence interval [CI], 17–38%). Twenty-eight
(39%) patients had stable disease, and 15 (21%) patients had
progressive disease.
Progression-Free Survival and Overall Survival
The median PFS was 6.2 months (95% CI, 4.1–8.1
months) (Figure 1). Six-month PFS was 51.6% (95% CI,
37.2–64.3%); 1-year PFS was 13.0% (95% CI, 4.3–26.6%).
The median OS was 8.5 months (95% CI, 6.7–11.5 months;
Figure 1). Six-month OS was 63.9% (95% CI, 51.7–73.8%);
1-year OS was 37.5% (95% CI, 26.7–48.5%); 2-year OS was
16.7% (95% CI, 9.2–26.1%).
Treatment-Related Toxicity
Treatment-related toxicity is summarized in Table 2. In
general, the regimen was well tolerated. Four (6%) patients
had chemotherapy held, and nine (13%) patients had chemo-
therapy reduced for hematologic toxicity. Grade 4 neutro-
penic fever occurred in three (4%) patients overall. The most
common (5%) grade 3/4 toxicities were as follows: neutro-
penia (47%), leukopenia (31%), fatigue (25%), dyspnea
(18%), pain (11%—abdominal, chest, and bone), and anemia
(8%). Alopecia occurred in 8%, and grade 3/4 nausea was
limited to 3%, with no severe vomiting observed. Four
patients developed pulmonary emboli, including one death.
FIGURE 1. A, Progression-free survival (PFS); B, overall survival (OS).
TABLE 1. Baseline Characteristics
Characteristic Patients, N (%)
Age (yr)
Median 66
Range 41–85
Gender
Male 47 (65%)
Female 25 (35%)
ECOG performance status
0 14 (19%)
1 48 (67%)
2 10 (14%)
Histology
Adenocarcinoma 26 (36%)
Squamous 9 (13%)
Large cell 13 (18%)
Mixed 2 (3%)
NSCLC, not otherwise specified 22 (31%)
Stage
IIIB 16 (22%)
IV 56 (78%)
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One patient died of pneumonia. All other grade 3/4 hemato-
logic and nonhematologic toxicities were uncommon (5%).
DISCUSSION
Multiple doublet regimens are considered acceptable
for first-line treatment in advanced NSCLC because of sim-
ilar response and survival benefits.1 Nonplatinum regimens
using newer cytotoxic agents maintain treatment efficacy and
improve related toxicity compared with platinum-based dou-
blets.2–5 Pemetrexed and gemcitabine are commonly used as
single agents in the second- and third-line treatment settings
because of modest activity and excellent safety profiles.6–9
This trial was designed to study the activity and safety of
combining these agents in the first-line setting.
This trial demonstrated that these two agents could be
safely combined and achieve a response rate that is similar to
other first-line doublet outcomes. Ma et al.10 similarly studied
a combination of pemetrexed and gemcitabine in the first-line
setting using three different schedules and achieved response
rates ranging from 7 to 31%, and a median survival and time
to progression of 11.4 and 4.4 months, respectively (no
difference between schedules). Our efficacy results were also
similar to recent platinum-based comparisons of gemcitabine
and pemetrexed in two phase III studies.14,15 Platinum/pem-
etrexed and platinum/gemcitabine were associated with sur-
vivals ranging from 7 to 10 months for each combination
(response rates not reported).
The large majority of patients (87%) on biweekly
treatment were able to stay on planned treatment without dose
reduction for hematologic toxicity. Grade 3/4 neutropenia
was observed in 47% of patients; however, only three patients
developed neutropenic fever. Of note, in the platinum-based
phase III trials comparing pemetrexed and gemcitabine, se-
vere neutropenia was seen in 15 to 40% with platinum/
pemetrexed and 27 to 51% with platinum/gemcitabine. In
addition, several bothersome nonhematologic side effects
were uncommon with this regimen, including alopecia, nau-
sea, and vomiting. However, fatigue was more notable in this
trial than reported with cisplatin/pemetrexed or cisplatin/
gemcitabine (25% versus 5–7%). Finally, it is important to
note that treatment could be administered in under an hour
and without the risk of hypersensitivity infusion reactions that
occur with taxane and platinum combinations.
This trial was designed to evaluate biweekly scheduling
as a means of delivering greater dose intensity with pem-
etrexed which, in theory, could improve efficacy. Biweekly
scheduling allows 50% more pemetrexed to be delivered over
6 weeks compared with every 3-week dosing as in the trial by
Ma et al.10 although with 10% less gemcitabine. Our results
did not suggest an efficacy advantage for biweekly schedul-
ing. Recently, Ohe at al. compared high-dose pemetrexed
(1000 mg/m2, 3-week dosing) with standard dosing (500
mg/m2, 3-week dosing) and similarly found no efficacy ad-
vantage with a minimal increase in toxicity.16 Attempting to
improve the treatment efficacy by increasing dose intensity
has not proven to be a successful strategy in other NSCLC
studies to date.17–19 Another potential advantage of biweekly
scheduling is shortening total treatment duration (four cycles
in 8 weeks versus 12 weeks with every 3-week dosing).
However, this trial was designed to deliver 4 to 6 months of
total therapy because of this regimen’s estimated ease of
delivery and overall safety.
This trial was limited by its single cohort design and
size to allow any formal comparisons with other doublet
regimens or to adequately assess survival outcomes. In addi-
tion, physicians were not required to perform CT scanning at
regular intervals in the follow-up period, although chest
x-rays were used to prompt such formal assessments. Finally,
with the emerging evidence that benefit of pemetrexed seems
to be limited to patients with nonsquamous tumors,15,20 the
inclusion of patients with squamous cancer in this trial
adversely affected the efficacy results. In a randomized phase
III trial comparing first-line cisplatin and pemetrexed with
cisplatin and gemcitabine, there was no difference in OS
(10.3 months). However, a preplanned subset analysis by
histology revealed a survival advantage for pemetrexed in
patients with nonsquamous tumors (11.8 months versus 10.4
months, respectively; hazard ratio  0.81; 95% CI 0.70–
0.94; P  0.005). Conversely, gemcitabine resulted in a
survival advantage in patients with squamous tumors (10.8
months versus 9.4 months). In an unplanned retrospective
analysis of patients with squamous and nonsquamous histol-
ogies in our study, the ORR was 3% and 23%, respectively.
The fact that only nine patients had squamous tumors signif-
icantly limits subset analysis.
In summary, pemetrexed and gemcitabine can be safely
combined in a biweekly schedule in the patients with previ-
ously untreated advanced NSCLC. In this phase II trial, this
regimen produced response rates similar to standard first-line
platinum-taxane combinations. In addition, the favorable tox-
icity profile makes this regimen an attractive platform for the
addition of novel agents. The addition of bevacizumab to this
pemetrexed/gemcitabine combination is one such regimen
that is worthy of further evaluation in a nonsquamous patient
population. Alternatively, a short course of treatment with
pemetrexed/gemcitabine (i.e., four courses in 8 weeks) may
provide an active, well-tolerated option for elderly and/or
poor performance status patients, and it merits further inves-
tigation.
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TABLE 2. Grade 3 and 4 Toxicity in 5% of Patients (N  72)
Toxicity Grade 3 Grade 4
Neutropenia 18 (25%) 16 (22%)
Leukopenia 17 (24%) 5 (7%)
Fatigue 17 (24%) 0
Dyspnea 12 (17%) 1 (1%)
Pain 8 (11%) 0
Anemia 6 (8%) 0
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